Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

BackgroundAlzheimers disease (AD) pathology often accumulates years before memory loss, creating a need to identify high-risk individuals presymptomatically. Polygenic risk scores (PRS) stratify AD risk, but individual-level predictions remain uncertain. Extreme PRS may identify high-risk individuals independent of APOE. MethodsUsing GenoPred, extreme tails of 1,752 PRS methods were evaluated across four genetic ancestries using 11,200 autopsy- or clinically-defined AD cases and 19,321 controls (age [≥]65) from the AD Sequencing Project (ADSP) Release 5. ResultsIndividuals in the extreme upper PRS tail were significantly enriched for AD in all ancestries: Admixed American (Padj=0.02727), African (Padj=0.004827), East Asian (Padj=0.02824), and European (Padj=2.3068x10-13). No controls were observed among the 42 European- and 12 African-ancestry individuals with extreme PRS. Extreme PRS spanned APOE diplotypes; 38% occurred in non-APOE {varepsilon}4 carriers. ConclusionsRare subsets of individuals at the most extreme PRS thresholds have markedly elevated AD enrichment across ancestries and APOE diplotypes. Data AvailabilityAll data are available through the ADSP, which is managed by The National Institute on Aging Genetics of Alzheimers Disease Data Storage Site (NIAGADS).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ward, E. L., Nelson, P. T., Katsumata, Y., Fardo, D. W., Jicha, G. A., Alzheimer's Disease Neuroimaging Initiative,, et al. (2026). Rare extreme polygenic risk scores strongly indicate Alzheimer's disease risk. medRxiv (preprint). https://doi.org/10.64898/2026.09.08.26362504

Vancouver

Ward EL, Nelson PT, Katsumata Y, Fardo DW, Jicha GA, Alzheimer's Disease Neuroimaging Initiative,, et al. Rare extreme polygenic risk scores strongly indicate Alzheimer's disease risk. medRxiv (preprint). 2026. doi:10.64898/2026.09.08.26362504.

BibTeX

@article{ward2026-c1a7a162,
  author  = {Ward, E. L. and Nelson, P. T. and Katsumata, Y. and Fardo, D. W. and Jicha, G. A. and {Alzheimer's Disease Neuroimaging Initiative,} and Miller, J. B.},
  title   = {{Rare extreme polygenic risk scores strongly indicate Alzheimer's disease risk}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.09.08.26362504},
  url     = {https://doi.org/10.64898/2026.09.08.26362504}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that people with extreme high polygenic risk scores were more likely to have Alzheimer's disease across ancestries, including some without the APOE ε4 variant. It is about identifying high-risk individuals, not about treating, curing, or preventing the disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 17 of the 94 points it could be judged on, which is 18 of 100. Raw total 18 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 18 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 18 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 17 of the 94 points we could judge it on, which is 18 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Justin B. Miller: h-index 16 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Kentucky: institution h-index 824 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 17 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 17 of the 94 points we could judge it on is 18 out of 100.
Total 18 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Genetics

Also tagged “precursor”

1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.

Similar studies

More on Genetics

See all studies in Genetics →